Asamoto M, Ochiya T, Toriyama-Baba H, Ota T, Sekiya T, Terada M, Tsuda H
Experimental Pathology and Chemotherapy Division, Genetics Division and Oncogene Division, National Cancer Center Research Institute, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Carcinogenesis. 2000 Feb;21(2):243-9. doi: 10.1093/carcin/21.2.243.
A rat line carrying three copies of the human c-Ha-ras proto-oncogene, including its own promoter region, was established and designated Hras128. Expression of the transgene was detected in all organs examined from Hras128 rats by northern blot analysis. To examine its influence on susceptibility to N-methyl-N-nitrosourea (MNU)-induced mammary carcinogenesis, female rats were treated with 50 mg/kg MNU i.v. at 50 days of age. All 22 Hras128 transgenic rats rapidly developed multiple and large mammary carcinomas within as little as 8 weeks after MNU treatment (14.1 tumors/rat, average diameter 16.4 mm). In contrast, 24 non-transgenic littermates developed no or only small tumors (0.46 tumors/rat, average diameter 7.4 mm) within this period. PCR-restriction fragment length polymorphism (RFLP) analysis and direct sequencing for the transduced human c-Ha-ras proto-oncogene indicated that 38 out of 44 tumors (86.4%) contained cells with mutations at codon 12 in exon 1. However, the signal densities of the mutated bands observed in the RFLP analyses revealed the presence of mixed populations of mutated and non-mutated cells in the tumors, the latter being in the majority. PCR-single strand conformation polymorphism analysis detected no mutations in codons 12 or 61 of the endogenous rat c-Ha-ras gene of Hras128 rat tumors. The results thus indicate that rats carrying the transduced human c-Ha-ras proto-oncogene are highly susceptible to MNU-induced mammary carcinogenesis and that this is not primarily due to mutations of the transgene or endogenous c-Ha-ras gene.
建立了一个携带三份人类原癌基因c-Ha-ras(包括其自身启动子区域)的大鼠品系,并命名为Hras128。通过Northern印迹分析在Hras128大鼠的所有检测器官中检测到转基因的表达。为了研究其对N-甲基-N-亚硝基脲(MNU)诱导的乳腺癌发生易感性的影响,在50日龄时对雌性大鼠静脉注射50 mg/kg MNU。所有22只Hras128转基因大鼠在MNU处理后短短8周内迅速发生多个大的乳腺癌(14.1个肿瘤/大鼠,平均直径16.4 mm)。相比之下,24只非转基因同窝大鼠在此期间未发生肿瘤或仅发生小肿瘤(0.46个肿瘤/大鼠,平均直径7.4 mm)。对转导的人类原癌基因c-Ha-ras进行PCR-限制性片段长度多态性(RFLP)分析和直接测序表明,44个肿瘤中有38个(86.4%)含有第1外显子密码子12处发生突变的细胞。然而,在RFLP分析中观察到的突变条带的信号密度表明肿瘤中存在突变和未突变细胞的混合群体,后者占多数。PCR-单链构象多态性分析未检测到Hras128大鼠肿瘤内源性大鼠c-Ha-ras基因密码子12或61处的突变。因此,结果表明携带转导的人类原癌基因c-Ha-ras的大鼠对MNU诱导的乳腺癌发生高度敏感,这主要不是由于转基因或内源性c-Ha-ras基因的突变。